
Zymeworks Inc. (NASDAQ:ZYME) stock is surging on Monday, with a session volume of 2.17 million, compared to an average volume of 728.75K, according to Benzinga Pro.
Zymework, along with its partners, Jazz Pharmaceuticals Inc. (NASDAQ:JAZZ) and BeOne Medicines Inc. (NASDAQ:ONC), announced topline results from the Phase 3 HERIZON-GEA-01 trial.